drugset / Trial / NCT01006252

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

NCT01006252

Phase 3 Terminated 336 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.

Timeline

Start
2009-12
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Paclitaxel Small molecule 80 mg/m2 Intravenous
Subject Tasisulam Small molecule Intravenous

Indications